Is Anlon Healthcare the Best Stock in Its Sector? A Look at the Numbers
- September 23, 2026
- Posted by: Harsh Piplani
- Category: Market
Anlon Healthcare CMP Rs 29 (23 Sep 2026). Market cap Rs 1,544 Cr. ROE 12.38%. P/E 45.38x versus Industry P/E 38.56x.
Quick Answer
Anlon Healthcare is one of the names investors compare when screening the Chemicals sector, built on a 12.38% return on equity and a P/E of 45.38x against an Industry P/E of 38.56x. Whether Anlon Healthcare is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Chemicals sector peers, so you can judge that for yourself.
Is Anlon Healthcare the best stock in its sector? The stock trades on the NSE at Rs 29 as of 23 September 2026, within its 52-week range of Rs 10.37 to Rs 28.86. Anlon Healthcare Ltd manufactures pharmaceutical and agrochemical intermediates.
Anlon Healthcare sits in the Chemicals sector, and its 12.38% ROE and 45.38x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P/E benchmark.
Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers
Click Here – Get Free Investment Predictions
About Anlon Healthcare
Anlon Healthcare Ltd manufactures pharmaceutical and agrochemical intermediates. It manufactures pharmaceutical and agrochemical intermediates, and the stock is trading at a fresh 52-week high at the time of writing. At a market capitalisation of Rs 1,544 Cr, it is tracked as part of the Chemicals sector on Univest.
Is Anlon Healthcare the Best Stock in Its Sector?
Anlon Healthcare makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, combining a 12.38% ROE with a 45.38x P/E against the sector’s 38.56x Industry P/E. Anlon Healthcare’s 45.38x P/E is close to the 38.56x Industry P/E, with a 12.38% ROE that is a reasonable figure among the specialty chemical and pharma intermediate peers used elsewhere in this series, though the stock’s fresh 52-week high is worth noting.
| Metric | Anlon Healthcare |
|---|---|
| CMP (NSE) | Rs 28.86 |
| 52-Week High / Low | Rs 28.86 / Rs 10.37 |
| Market Cap | Rs 1,544 Cr |
| P/E (TTM) vs Industry P/E | 45.38x vs 38.56x |
| P/B | 6.70 |
| ROE | 12.38% |
| EPS (TTM) | Rs 0.64 |
| Dividend Yield | 0.00% |
| Debt to Equity | 0.19 |
Compare Anlon Healthcare Against Other Chemicals Sector Stocks
How Anlon Healthcare Compares Against Its Chemicals Sector Peers
The table below sets Anlon Healthcare against 2 other Chemicals sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.
| Company | Market Cap (Rs Cr) | P/E | ROE | Debt to Equity |
|---|---|---|---|---|
| Anlon Healthcare | 1,544 | 45.38 | 12.38% | 0.19 |
| Aarti Pharmalabs | 7,157 | 34.39 | 8.89% | 0.38 |
| Amines and Plasticizers | 963 | 24.96 | 12.50% | 0.09 |
| Peer average (2 companies) | – | 29.68 | 10.70% | 0.23 |
Against this peer set, Anlon Healthcare’s 12.38% ROE is above the 10.70% peer average, and its P/E of 45.38x runs above the peer average of 29.68x. Anlon Healthcare’s 45.38x P/E is close to the 38.56x Industry P/E, with a 12.38% ROE that is a reasonable figure among the specialty chemical and pharma intermediate peers used elsewhere in this series, though the stock’s fresh 52-week high is worth noting.
What Makes Anlon Healthcare Worth Watching in Chemicals
- Solid ROE: A 12.38% ROE is a reasonable figure for a pharma and agrochemical intermediates manufacturer.
- Low leverage: A debt to equity ratio of 0.19 is manageable for a specialty chemicals manufacturer.
- Trading at a fresh 52-week high: The stock is currently at its 52-week high, reflecting strong recent momentum that investors should weigh alongside the fundamentals.
Anlon Healthcare Valuation: Is It Justified?
Anlon Healthcare’s 45.38x P/E is close to the 38.56x Industry P/E, with a 12.38% ROE that is a reasonable figure among the specialty chemical and pharma intermediate peers used elsewhere in this series, though the stock’s fresh 52-week high is worth noting. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.
Also read – Is Allied Blenders and Distillers the Best Stock in Its Sector? A Look at the Numbers
Download the Univest iOS App or Univest Android App to track Anlon Healthcare and other Chemicals sector stocks.
How to Track Anlon Healthcare Before You Invest
Before deciding whether Anlon Healthcare deserves its label as the best stock in its sector for your own portfolio, compare it directly against Chemicals sector peers using the steps below.
- Open the Univest Screener and search for Anlon Healthcare to view live price, valuation ratios, and peer comparisons within the Chemicals sector.
- Compare its P/E, P/B, and ROE against other Chemicals sector stocks before deciding if the current valuation fits your strategy.
- Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
- Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.
Conclusion
Anlon Healthcare earns a place in the best stock in its sector conversation on the strength of a 12.38% ROE and a P/E of 45.38x against a 38.56x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Is Anlon Healthcare the best stock in its sector?
Ans. Anlon Healthcare has a 12.38% ROE and trades at 45.38x P/E against a 38.56x Industry P/E, and compares above the peer average ROE of 10.70% in this article’s named comparison, so the answer depends on what an investor is prioritising.
What is the current share price of Anlon Healthcare?
Ans. Anlon Healthcare was trading at Rs 28.86 on the NSE as of 23 September 2026, within its 52-week range of Rs 10.37 to Rs 28.86.
What sector does Anlon Healthcare belong to?
Ans. Anlon Healthcare is classified under the Chemicals sector on Univest.
How does Anlon Healthcare compare to its sector peers on P/E?
Ans. Anlon Healthcare’s P/E of 45.38x is above the 29.68x average of the 2 named peers compared in this article.
What is Anlon Healthcare’s return on equity?
Ans. Anlon Healthcare reported a return on equity of 12.38%, which is above the 10.70% average of its named peers in this comparison.
Should I invest in Anlon Healthcare based on its sector position?
Ans. Anlon Healthcare’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.
